Auransa is a clinical stage drug development company who aims to invent high value, novel drugs for hard-to-treat diseases like cancer, auto-immune and neurological disorders using its proprietary AI platform and drug discovery expertise. The company's platform is used to understand biology of diseases at subtype level resolution, enabling it to predict compounds and targets of novel pharmacology for responder patient population. Current internal drug pipeline includes a first-in-class investigational new drug for cancer in clinical trials. Auransa has partnership with companies and institutions in the biopharma industry.

Professional Dietetics is a healthcare product developer. Professional Dietetics is committed to the discovery, development, approval, and marketing of foods for special medical purposes, food supplements, and medical devices. They identify and develop science-driven solutions to meet the needs of patients and doctors across a wide range of therapeutic areas and clinical indications.

Signpath Pharma is a development stage biotechnology company founded in 2006. Its lead compound is 99.2% pure synthesized curcumin (diferuloylmethane). Curcumin has an extensive and long history in humans as a mixture of naturally occurring curcuminoids in extracts of the root of the Curcuma longa plant. Traditional use of curcumin has been restricted to topical skin and gastrointestinal conditions because of negligible absorption when given orally. To extend its clinical use Signpath is developing three different intravenous nanoparticle-sized formulations; liposomal, polymeric, and PLGA. Proof of efficacy of these formulations against human tumor xenografts in mice has been established. Following intravenous injection of each formulation, we observed transport across the blood brain barrier in mice, rats, and localization in the hippocampus, brainstem and the striatum.

ZEON Corp. engages in the production and sale of synthetic rubbers and specialty plastics. It operates through the following segments: Elastomer Materials Business, Specialty Materials Business, and Others. The Elastomer Materials Business segment includes synthetic rubbers used in automobile tires and conveyer belts; synthetic lattices used in tires and adhesives; and chemical products such as resins and inks. The Specialty Materials Business segment comprises of synthetic aroma chemicals and other industrial chemicals; information and imaging materials; specialty plastics for optical lenses; and medical products. The Others segment consists of paints, butadiene extraction technology, and reaction injection molding (RIM) formulations and products. The company was founded on April 12, 1950 and is headquartered in Tokyo, Japan.

Otsuka Holdings operates in pharmaceuticals, nutraceuticals, and consumer products. The business activity of the company includes providing healthcare solutions in the areas of the nervous system, oncology, cardiovascular system, respiratory system, infectious disease, and others. The company engages in the research and development of functional foods and beverages, such as electrolyte drinks, nutritional foods, soy snacks, and dietary foods.

Jiangsu Enhua Pharmaceutical Co., Ltd. is strategically positioned in the central nervous drug market, mainly engaged in the development, production and sales of central nervous system drugs. It is a company specializing in the market segment of central nervous drugs. The main categories include anesthesia and spirit. Class and Neurology, through years of unremitting efforts in product development, production and service, the company has established a complete series of central nervous system drug products and marketing network, and strive to build an important domestic producer and sales of central nervous system drugs. Business.

StemBioSys, Inc. develops stem cell technologies. The firm develops technology on the isolation and expansion of specialized adult stem cells for clinical use. Its technology is called XC-marrowECM, which is a patented extracellular matrix laid down by human bone marrow mesenchymal stem cells. The company was founded by Xiao-Dong Chen and Steven A. Davis in 2010 and is headquartered in San Antonio, TX.

Hanyuan Pharmaceutical Co., Ltd., established on 2019-11-05, Business scope includes general items:Medical Research and Experimental Development;Natural science research and experimental development;Engineering and Technology Research and Experimental Development;Human stem cell technology development and application;R&D and application of cell technology;Health Consulting Services(Does not include medical services);Development of Human Gene Diagnosis and Therapy Technology;Extraction of marine bioactive substances,purification,Synthesis technology research and development;New material technology research and development;Business Management Consulting;Information Consulting Service(Not including licensing information consulting services);Consulting and planning service;market survey(Does not include foreign investigations);marketing planning;Information Technology Consulting Services;Information system integration service;Computer System Services;data processing services;Information system operation and maintenance services;software development;Artificial intelligence application software development;Network and Information Security Software Development;Experimental analysis instrument sales;Smart Instrument Sales;Information security equipment sales;Retailing of computer software, hardware and auxiliary equipment;Additive Manufacturing Equipment Sales;Sales of building decoration materials;Engineering Management Services;Engineering technical service(planning management,survey,design,Except supervision);General machinery and equipment installation services;Industrial Engineering Design Services;Technical Services,technology development,technical consulting,Technology Exchange,technology transfer,Technology Promotion.(Except for projects subject to approval by law,Carry out business activities independently in accordance with the law with a business license)licensed items:Technology Import and Export;Import and export;Various construction activities;General contracting of housing construction and municipal infrastructure projects;Engineering cost consulting business;Inspection and testing service.(Items subject to approval by law,Business activities can only be carried out after approval by relevant departments,The specific business items are subject to the approval documents or licenses of relevant departments)

Faraday Pharmaceuticals is an early-stage therapeutics company focused on developing novel therapies to treat ischemia-reperfusion injury. It has in-licensed proprietary liquid formulations of reduced nonmetal gaseous elements developed in the lab of Dr. Mark Roth at the Fred Hutchinson Cancer Center. The company was founded in 2014 and is located in Seattle, Washington.

Stem Cell Theranostics, Inc. develops genetically-targeted therapies for genetic and drug-induced heart disease. It offers a discovery platform that focuses on the generation and use of stem cell-derived, patient-specific cardiac models in drug screening and therapeutic development. The company was founded by Andrew Lee, Robert C. Robbins, Divya Nag, and Joseph C. Wu in 2013 and is headquartered in Redwood City, CA.

Part of CSPC Pharmaceutical Group Ltd., CSPC Zhongqi Pharmaceutical Technology Shijiazhuang Co., Ltd. is a company headquartered in China. The firm engages in pharmaceutical research and development.

Xenon Pharmaceuticals is a biopharmaceutical company focused on the development of novel medicines through the application of our proprietary discovery platform, which we refer to as Extreme Genetics. Our product candidates are based on genetic insights derived from our research of families where individuals exhibit severe traits or phenotypes. They apply their expertise to predict which phenotypes are caused by single-gene defects. By identifying and characterizing the single-gene defects responsible for such severe phenotypes, they gain valuable insights into their function in human biology and their potential as drug targets. Given that these targets are often involved in diseases beyond the rare genetic disorders in which they are first identified, they are developing proprietary product candidates to treat both orphans as well as more prevalent diseases

Berg is a Swiss private company located in Berg, with subsidiaries in Spain, providing investment services.

China State Institute of Pharmaceutical Industry is a company headquartered in Shanghai, China and ultimately controlled by the Government of China. The firm regulates pharmaceutical companies.

G.D. Searle, LLC is a wholly owned trademark of Pfizer. It is currently used mainly as a distribution trademark for various pharmaceuticals that were developed by G. D. Searle & Company (often referred to as Searle). Prior to its 1985 merger with Monsanto, Searle was a company focusing on life sciences, specifically pharmaceuticals, agriculture, and animal health.

Shanghai Zhongze Pharmaceutical Technology Co., Ltd., established on 2017-09-08, Business scope includes general items:Engaged in technology development in the field of medical science and technology,technical consulting,Technical Services,technology transfer(remove human stem cells,Development and application of genetic diagnosis and treatment technology);Expo Services;translation service;Health Advisory(except for medical diagnosis);Business Consulting(Does not include investment consulting);Business Management Consulting;marketing planning;Corporate Image Planning;computer software development(Audio-visual products,Except for electronic publications);sales of cosmetics.(Except for projects subject to approval by law,Carry out business activities independently in accordance with the law with a business license)

Abbott Products SAS provides pharmaceutical products. The company is headquartered in Suresnes, France.

At Molecular Devices, they enable their customers to unravel the complexity of biological systems. Their innovative analytical solutions for cell and protein biology enable our customers to see more, do more, and know more, and to answer life's most important questions. They are one of the world’s leading providers of high-performance bioanalytical measurement solutions for life science research, pharmaceutical and biotherapeutic development. With over 130,000 placements in laboratories around the world, our instruments have catalyzed brilliant scientific research described in over 25,000 peer reviewed publications. Included within a broad product portfolio are platforms for high-throughput screening, genomic and cellular analysis, colony selection and microplate detection. These leading-edge products empower scientists to improve productivity and effectiveness, ultimately accelerating research and the discovery of new therapeutics. Their headquarters are in Silicon Valley, the hub of technology and innovation, with offices around the globe employing close to 1,000 highly skilled and passionate associates.

Merrimack Pharmaceuticals, Inc. is a clinical stage biopharmaceutical company. engages in discovering, developing, and commercializing medicines consisting of novel therapeutics paired with diagnostics for the treatment of cancer. Its pipeline includes MM-131, MM-141, and MM-310. The company was founded by Anthony J. Sinskey, Gavin MacBeath, and Ulrik B. Nielsen in 1993 and is headquartered in Cambridge, MA.

Nippon Zeon Co., Ltd., part of BASF SE, is a company headquartered in Tokyo, Japan. The firm manufactures speciality liquid resins. It was acquired by Ciba Holding AG on March 01, 1998.